Osteoporosis Prevalence in Epilepsy Patients
Between 11-58% of patients with epilepsy develop osteoporosis, with the most robust recent evidence suggesting approximately 11-31% prevalence in adults on antiseizure medications, though rates can reach 58% in pediatric populations with additional risk factors. 1, 2
Evidence-Based Prevalence Data
The prevalence varies significantly based on patient population and risk factors:
Adult Populations
- General epilepsy patients on ASMs: 11-31% develop osteoporosis 1
- Institutionalized patients with refractory epilepsy: 43% of males and 21% of females have BMD in the osteoporotic range 3
- Community-dwelling patients: 11% have frank osteoporosis, with an additional 52% showing low bone mineral density (osteopenia) 4
Pediatric and Young Adult Populations
- 58.3% have abnormal BMD, with 75% showing osteopenia and 25% showing osteoporosis 2
- 10.1% have pronounced osteoporosis in patients on long-term (>3 years) anticonvulsants, with an additional 41.2% showing osteopenia 5
Key Risk Factors Affecting Prevalence
The wide range in prevalence reflects several critical modifiers:
Medication-related factors:
- Both enzyme-inducing ASMs (phenytoin, carbamazepine, phenobarbital) and non-enzyme-inducing ASMs independently increase osteoporosis risk 6
- Long-term treatment (>3 years) significantly increases prevalence 5
- Polytherapy carries higher risk than monotherapy 1
Patient-specific factors:
- Male gender shows higher rates (43% vs 21% in institutionalized patients) 3
- Lack of autonomous gait and severe mental retardation significantly correlate with abnormal BMD 2
- Younger patients with chronic epilepsy are particularly affected 3
Clinical Significance
Epilepsy independently increases osteoporosis risk by 41% faster time to development, even when controlling for other risk factors 6. This translates to a 2-6 times increased fracture risk compared to the general population 1.
Important Clinical Caveat
The majority of epilepsy patients (>50%) do not engage in bone-protective behaviors, and many are unaware of their risk 4. This represents a critical gap in preventive care that directly impacts morbidity through increased fracture risk.
Practical Implications
Given these prevalence rates, routine bone health screening should be considered standard practice for all patients with epilepsy, particularly those on long-term ASM therapy, males, institutionalized patients, and those with mobility limitations 1, 7. The evidence strongly supports proactive surveillance rather than waiting for clinical manifestations of reduced bone density 5.